Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Apatinib on Repaglinide and Bupropion in Advanced Solid Tumors
NCT04457180Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in solid tumor, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at Day 12 and Area Under the Curve at Day 12. Started Nov 2020; status: completed.
02
Drugs
Rivoceranib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04457180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457180.